With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1616415-40-7,(S)-tert-Butyl 4-(6-amino-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
To Intermediate 11 (0.31 g, 0.86 mmol) was added 4N HC1 in 1,4-dioxane (10 mL) and the mixture was stirred at r.t. DCM (10 mL) was added to aid solubility. The mixture was stirred at r.t. for 6 h before concentration in vacuo, to yield the title compound (0.29 g, 90.51%) as an off white solid. LCMS (ES+) 262.2 [M+H]+, RT 1.04 minutes (method 1)., 1616415-40-7
As the paragraph descriping shows that 1616415-40-7 is playing an increasingly important role.
Reference£º
Patent; UCB PHARMA S.A.; KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D; FORD, Daniel James; FRANKLIN, Richard Jeremy; GHAWALKAR, Anant Ramrao; HORSLEY, Helen Tracey; HUANG, Qiuya; REUBERSON, James Thomas; VANDERHOYDONCK, Bart; WO2014/96423; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics